(Reuters) - Lawmakers will examine this week how the FDA and manufacturer GlaxoSmithKline Plc handled data that suggested the pill Avandia might raise the chances of having a heart attack.
The controversy comes as Congress considers legislation meant to bolster the FDA's oversight of drug side effects. Some critics are using the Avandia case to try to build support for tougher safeguards.
Read more at Reuters.com Government Filings News
The controversy comes as Congress considers legislation meant to bolster the FDA's oversight of drug side effects. Some critics are using the Avandia case to try to build support for tougher safeguards.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment